Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Corrigendum
Letter to the Editor
BioMed Research International
Volume 2015, Article ID 724715, 10 pages
http://dx.doi.org/10.1155/2015/724715
Research Article

Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia Gravis

1Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150081, China
2Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
3College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China

Received 11 August 2014; Accepted 10 December 2014

Academic Editor: Dongchun Liang

Copyright © 2015 Yuze Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. N. Meriggioli and D. B. Sanders, “Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity,” The Lancet Neurology, vol. 8, no. 5, pp. 475–490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Guo, N. T. Ingolia, J. S. Weissman, and D. P. Bartel, “Mammalian microRNAs predominantly act to decrease target mRNA levels,” Nature, vol. 466, no. 7308, pp. 835–840, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. W. P. Kloosterman and R. H. A. Plasterk, “The diverse functions of microRNAs in animal development and disease,” Developmental Cell, vol. 11, no. 4, pp. 441–450, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Le Panse and S. Berrih-Aknin, “Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation,” Current Opinion in Neurology, vol. 26, no. 5, pp. 569–576, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Cheng, S. Qiu, L. Jiang et al., “MiR-320a is downregulated in patients with Myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1,” Journal of Clinical Immunology, vol. 33, no. 3, pp. 567–576, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Jiang, Z. Cheng, S. Qiu et al., “Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells,” International Immunopharmacology, vol. 14, no. 2, pp. 217–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Lu, M. Yan, Y. Wang et al., “Altered expression of miR-146a in myasthenia gravis,” Neuroscience Letters, vol. 555, pp. 85–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Nogales-Gadea, A. Ramos-Fransi, X. Suarez-Calvet et al., “Analysis of serum miRNA profiles of myasthenia gravis patients,” PLoS ONE, vol. 9, no. 3, Article ID e91927, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Auret, A. Abrahams, S. Prince, and J. M. Heckmann, “The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravis,” Neuromuscular Disorders, vol. 24, no. 6, pp. 499–508, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Kellermayer, N. Polgar, J. Pal et al., “Association of myasthenia gravis with polymorphisms in the gene of histamine N-methyltransferase,” Human Immunology, vol. 74, no. 12, pp. 1701–1704, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. X. B. Wang, R. Pirskanen, R. Giscombe, and A. K. Lefvert, “Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis,” Journal of Internal Medicine, vol. 263, no. 1, pp. 61–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. K. Lefvert, Y. Zhao, R. Ramanujam, S. Yu, R. Pirskanen, and L. Hammarström, “PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis,” Journal of Neuroimmunology, vol. 197, no. 2, pp. 110–113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Avidan, R. Le Panse, S. Berrih-Aknin, and A. Miller, “Genetic basis of myasthenia gravis—a comprehensive review,” Journal of Autoimmunity, vol. 52, pp. 146–153, 2014. View at Google Scholar
  14. Y.-Z. Wang, F.-F. Tian, M. Yan et al., “Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis,” Clinical and Experimental Immunology, vol. 176, no. 2, pp. 207–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Chen, H. Wang, L. Zhang et al., “Uncovering packaging features of co-regulated modules based on human protein interaction and transcriptional regulatory networks,” BMC Bioinformatics, vol. 11, article 392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Le Panse, G. Cizeron-Clairac, J. Bismuth, and S. Berrih-Aknin, “Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia,” The Journal of Immunology, vol. 177, no. 11, pp. 7868–7879, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. B. John, A. J. Enright, A. Aravin, T. Tuschl, C. Sander, and D. S. Marks, “Human microRNA targets,” PLoS Biology, vol. 2, no. 11, article e363, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Garcia, D. Baek, C. Shin, G. W. Bell, A. Grimson, and D. P. Bartel, “Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs,” Nature Structural and Molecular Biology, vol. 18, no. 10, pp. 1139–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. D. Paraskevopoulou, G. Georgakilas, N. Kostoulas et al., “DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows,” Nucleic Acids Research, vol. 41, no. 1, pp. W169–W173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Betel, A. Koppal, P. Agius, C. Sander, and C. Leslie, “Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites,” Genome Biology, vol. 11, no. 8, article R90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Krek, D. Grün, M. N. Poy et al., “Combinatorial microRNA target predictions,” Nature Genetics, vol. 37, no. 5, pp. 495–500, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. C. Miranda, T. Huynh, Y. Tay et al., “A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes,” Cell, vol. 126, no. 6, pp. 1203–1217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Krüger and M. Rehmsmeier, “RNAhybrid: microRNA target prediction easy, fast and flexible,” Nucleic Acids Research, vol. 34, pp. W451–W454, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kertesz, N. Iovino, U. Unnerstall, U. Gaul, and E. Segal, “The role of site accessibility in microRNA target recognition,” Nature Genetics, vol. 39, no. 10, pp. 1278–1284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Wang, “miRDB: a microRNA target prediction and functional annotation database with a wiki interface,” RNA, vol. 14, no. 6, pp. 1012–1017, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Bandyopadhyay and R. Mitra, “TargetMiner: microRNA target prediction with systematic identification of tissue-specific negative examples,” Bioinformatics, vol. 25, no. 20, pp. 2625–2631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Dennis Jr., B. T. Sherman, D. A. Hosack et al., “DAVID: database for annotation, visualization, and integrated discovery,” Genome Biology, vol. 4, no. 5, article P3, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Li, X. Li, Y. Miao et al., “SubpathwayMiner: a software package for flexible identification of pathways,” Nucleic Acids Research, vol. 37, no. 19, article e131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Wu, C. Li, P. Zhang et al., “Dissection of miRNA-miRNA interaction in esophageal squamous cell carcinoma,” PLoS ONE, vol. 8, no. 9, Article ID e73191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. K. K.-H. Farh, A. Grimson, C. Jan et al., “Biochemistry: The widespread impact of mammalian MicroRNAs on mRNA repression and evolution,” Science, vol. 310, no. 5755, pp. 1817–1821, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Li, C. Qiu, J. Tu et al., “HMDD v2.0: a database for experimentally supported human microRNA and disease associations,” Nucleic Acids Research, vol. 42, no. 1, pp. D1070–D1074, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. Q. Jiang, Y. Wang, Y. Hao et al., “miR2Disease: a manually curated database for microRNA deregulation in human disease,” Nucleic Acids Research, vol. 37, no. 1, pp. D98–D104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Fenoglio, C. Cantoni, M. de Riz et al., “Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis,” Neuroscience Letters, vol. 504, no. 1, pp. 9–12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Meisgen, N. Xu, T. Wei et al., “miR-21 is up-regulated in psoriasis and suppresses T cell apoptosis,” Experimental Dermatology, vol. 21, no. 4, pp. 312–314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Stagakis, G. Bertsias, P. Verginis et al., “Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: MiR-21 regulates aberrant T cell responses through regulation of PDCD4 expression,” Annals of the Rheumatic Diseases, vol. 70, no. 8, pp. 1496–1506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Kozomara and S. Griffiths-Jones, “MiRBase: Integrating microRNA annotation and deep-sequencing data,” Nucleic Acids Research, vol. 39, no. 1, pp. D152–D157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Altuvia, P. Landgraf, G. Lithwick et al., “Clustering and conservation patterns of human microRNAs,” Nucleic Acids Research, vol. 33, no. 8, pp. 2697–2706, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Arimori and Z. J. Song, “Expression of c-myc, c-Ki-ras and c-Ha-ras oncogene products in peripheral blood mononuclear cells from patients with myasthenia gravis,” Internal Medicine, vol. 32, no. 7, pp. 519–522, 1993. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Roskoski Jr., “ERK1/2 MAP kinases: structure, function, and regulation,” Pharmacological Research, vol. 66, no. 2, pp. 105–143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S.-H. Yang, A. D. Sharrocks, and A. J. Whitmarsh, “Transcriptional regulation by the MAP kinase signaling cascades,” Gene, vol. 320, no. 1-2, pp. 3–21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Colombara, V. Antonini, A. P. Riviera et al., “Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells,” The Journal of Immunology, vol. 175, no. 10, pp. 7021–7028, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. Q. Liu, H. Fu, F. Sun et al., “miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes,” Nucleic Acids Research, vol. 36, no. 16, pp. 5391–5404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Selbach, B. Schwanhäusser, N. Thierfelder, Z. Fang, R. Khanin, and N. Rajewsky, “Widespread changes in protein synthesis induced by microRNAs,” Nature, vol. 455, no. 7209, pp. 58–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Nishikawa, Y. Goto, S. Kojima et al., “Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer,” International Journal of Oncology, vol. 45, no. 1, pp. 401–410, 2014. View at Publisher · View at Google Scholar
  45. F. Weber, R. E. Teresi, C. E. Broelsch, A. Frilling, and C. Eng, “A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3584–3591, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Duan, B. Zhou, H. Su, Y. Liu, and C. Du, “MiR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300,” Experimental Cell Research, vol. 319, no. 3, pp. 173–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. W. Freilich, M. E. Woodbury, and T. Ikezu, “Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia,” PLoS ONE, vol. 8, no. 11, Article ID e79416, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. X. Li, W. Jiang, W. Li et al., “Dissection of human miRNA regulatory influence to subpathway,” Briefings in Bioinformatics, vol. 13, no. 2, Article ID bbr043, pp. 175–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Kojovic, M. Bologna, P. Kassavetis et al., “Functional reorganization of sensorimotor cortex in early Parkinson disease,” Neurology, vol. 78, no. 18, pp. 1441–1448, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Takeuchi, T. Chuma, Y. Matsuo, I. Watanabe, and K. Ikoma, “Repetitive transcranial magnetic stimulation of contralesional primary motor cortex improves hand function after stroke,” Stroke, vol. 36, no. 12, pp. 2681–2686, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Weiss, F. Mori, S. Rossi, and D. Centonze, “Disability in multiple sclerosis: when synaptic long-term potentiation fails,” Neuroscience and Biobehavioral Reviews, vol. 43, pp. 88–99, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Q.-S. Chen, B. L. Kagan, Y. Hirakura, and C.-W. Xie, “Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides,” Journal of Neuroscience Research, vol. 60, no. 1, pp. 65–72, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. P. de Candia, A. Torri, M. Pagani, and S. Abrignani, “Serum microRNAs as biomarkers of human lymphocyte activation in health and disease,” Frontiers in Immunology, vol. 5, article 43, 2014. View at Publisher · View at Google Scholar
  54. C. Xiao, D. P. Calado, G. Galler et al., “MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb,” Cell, vol. 131, no. 1, pp. 146–159, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Fallah, E. Arefian, M. Naderi et al., “MiR-146a and miR-150 promote the differentiation of CD133+ cells into T-lymphoid lineage,” Molecular Biology Reports, vol. 40, no. 8, pp. 4713–4719, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Sakamoto, K. Karelina, and K. Obrietan, “CREB: a multifaceted regulator of neuronal plasticity and protection,” Journal of Neurochemistry, vol. 116, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar
  57. W. Chen, X. Zeng, F. Luo, T. Lv, X. Zhou, and J. Bai, “The decreased expression of thioredoxin-1 in brain of mice with experimental autoimmune myasthenia gravis,” Neuromuscular Disorders, vol. 24, no. 8, pp. 726–735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. C.-F. Kao, P. Jia, Z. Zhao, and P.-H. Kuo, “Enriched pathways for major depressive disorder identified from a genome-wide association study,” International Journal of Neuropsychopharmacology, vol. 15, no. 10, pp. 1401–1411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Drago, C. Crisafulli, and A. Serretti, “The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 156, no. 8, pp. 975–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Pieples, G. Arteaga, R. John Solaro et al., “Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca2+ activation,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 283, no. 4, pp. H1344–H1353, 2002. View at Google Scholar · View at Scopus
  61. M. C. Dalakas, “Novel future therapeutic options in Myasthenia Gravis,” Autoimmunity Reviews, vol. 12, no. 9, pp. 936–941, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Paraskevi, G. Theodoropoulos, I. Papaconstantinou, G. Mantzaris, N. Nikiteas, and M. Gazouli, “Circulating MicroRNA in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 6, no. 9, pp. 900–904, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Dai, W. Sui, H. Lan, Q. Yan, H. Huang, and Y. Huang, “Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients,” Rheumatology International, vol. 29, no. 7, pp. 749–754, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. B. M. Conti-Fine, M. Milani, and H. J. Kaminski, “Myasthenia gravis: past, present, and future,” The Journal of Clinical Investigation, vol. 116, no. 11, pp. 2843–2854, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Li, P. Agarwal, and D. Rajagopalan, “A global pathway crosstalk network,” Bioinformatics, vol. 24, no. 12, pp. 1442–1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Hoesel and J. A. Schmid, “The complexity of NF-κB signaling in inflammation and cancer,” Molecular Cancer, vol. 12, no. 1, article 86, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. Z. Brys, A. Pluhar, J. Tibor Kis, B. Buda, and A. Szabo, “Network analysis of neurotransmitter related human kinase genes. Possible role of SRC, RAF1, PTK2B?” Neuropsychopharmacologia Hungarica, vol. 15, no. 3, pp. 165–171, 2013. View at Google Scholar · View at Scopus
  68. E. K. Kim and E. J. Choi, “Pathological roles of MAPK signaling pathways in human diseases,” Biochimica et Biophysica Acta, vol. 1802, no. 4, pp. 396–405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Uzawa, N. Kawaguchi, K. Himuro, T. Kanai, and S. Kuwabara, “Serum cytokine and chemokine profiles in patients with myasthenia gravis,” Clinical & Experimental Immunology, vol. 176, no. 2, pp. 232–237, 2014. View at Publisher · View at Google Scholar · View at Scopus